ABSTRACT
Objective: To study the outcome of patients with multiple sclerosis (MS) and with natalizumab-associated progressive multifocal leukoencephalopathy (PML) and immune reconstitution inflammatory syndrome (IRIS).
Methods: MedWatch reports from Biogen-Idec (manufacturer of natalizumab, Tysabri®) were reviewed which comprised all 42 cases of natalizumab-related PML cases since its reintroduction until March 2010.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768